Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nyse
  5. AbbVie Inc.
  6. News
  7. Summary
    ABBV   US00287Y1091

ABBVIE INC.

(ABBV)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
 SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies
Most relevant news about ABBVIE INC.
09/20ABBVIE : Seeks FDA Approval for Crohn's Disease Treatment Candidate
MT
09/20ABBVIE : Submits Regulatory Application to FDA for Risankizumab-rzaa (SKYRIZI®) for the Tr..
PR
09/16ABBVIE : Files Regulatory Applications in US and Europe for Upadacitinib to Treat Adults W..
MT
09/16ABBVIE : Submits Regulatory Applications to FDA and EMA for Upadacitinib (RINVOQ®) for the..
PR
09/16AbbVie Submits Regulatory Applications to FDA and EMA for Upadacitinib for the Treatmen..
CI
09/16AbbVie Submits Regulatory Applications for Treatment of Ulcerative Colitis
DJ
09/14ABBVIE : and REGENXBIO Announce Eye Care Collaboration
AQ
09/13ABBVIE : Declares Quarterly Dividend
AQ
09/13ABBVIE : to Highlight Its Leadership in Movement Disorders at the International Parkinson ..
AQ
09/13ABBVIE : REGENXBIO Join Forces on Therapy to Treat Chronic Eye Disorders
MT
09/13AbbVie, Regenxbio to Partner on Eye Therapy
DJ
09/10ABBVIE : Maintains Quarterly Cash Dividend at $1.30 a Share, Payable Nov. 15 to Shareholde..
MT
09/10ABBVIE : Declares Quarterly Dividend
PR
09/10AbbVie Inc. Declares Quarterly Dividend, Payable on November 15, 2021
CI
09/10ABBVIE : Clinical Trial of Investigational Epcoritamab (DuoBody-CD3xCD20) in Patients with..
AQ
More most relevant news
All news about ABBVIE INC.
09/20ABBVIE : Seeks FDA Approval for Crohn's Disease Treatment Candidate
MT
09/20ABBVIE : Submits Regulatory Application to FDA for Risankizumab-rzaa (SKYRIZI®) for the Tr..
PR
09/16ABBVIE : Files Regulatory Applications in US and Europe for Upadacitinib to Treat Adults W..
MT
09/16ABBVIE : Submits Regulatory Applications to FDA and EMA for Upadacitinib (RINVOQ®) for the..
PR
09/16AbbVie Submits Regulatory Applications to FDA and EMA for Upadacitinib for the Treatmen..
CI
09/16AbbVie Submits Regulatory Applications for Treatment of Ulcerative Colitis
DJ
09/15China's biotech sector comes of age with big licensing deals, global ambitions
RE
09/14ABBVIE : and REGENXBIO Announce Eye Care Collaboration
AQ
09/14REGENXBIO : RBC Lifts Price Target on REGENXBIO to $55 From $50, Sees Eye Care Deal With A..
MT
09/13Health Care Stocks Still Adding to Afternoon Slide
MT
More news
News in other languages on ABBVIE INC.
09/20AbbVie demande l'autorisation de la FDA pour un traitement candidat contre la maladie d..
09/16AbbVie dépose des demandes d'homologation aux États-Unis et en Europe pour l'upadacitin..
09/13Les actions du secteur de la santé continuent de s'enfoncer dans l'après-midi
09/13Les actions du secteur de la santé en baisse lundi après-midi
09/13REGENXBIO s'associe à AbbVie pour commercialiser le RGX-314 contre les maladies oculair..
09/13ABBVIE : partenariat avec Regenxbio
09/13Les valeurs à suivre aujourd'hui à Wall Street Lundi 13 septembre 2021
09/13ABBVIE : vers un accord de 1,8 milliard de dollars avec Regenxbio
09/10AbbVie Inc. Déclare un dividende trimestriel, payable le 15 novembre 2021
09/09The Lancet publie les résultats positifs de l'essai de phase 1/2 d'Epcoritamab de Genma..
More news
Analyst Recommendations on ABBVIE INC.
09/14REGENXBIO : RBC Lifts Price Target on REGENXBIO to $55 From $50, Sees Eye Care Deal With A..
MT
09/02ABBVIE : SVB Leerink Adjusts AbbVie PT to $142 From $148, Maintains Outperform Rating
MT
08/23ABBVIE : Cowen Adjusts AbbVie's Price Target to $130 From $120, Reiterates Outperform Rati..
MT
08/20ABBVIE : SVB Leerink Adjusts AbbVie's Price Target to $148 from $145, Keeps Outperform Rat..
MT
08/02ABBVIE : JPMorgan Adjusts AbbVie Price Target to $140 From $135, Maintains Overweight Rati..
MT
More recommendations
Press releases
09/20ABBVIE : Submits Regulatory Application to FDA for Risankizumab-rzaa (SKYRIZI®) for the Tr..
PR
09/16ABBVIE : Submits Regulatory Applications to FDA and EMA for Upadacitinib (RINVOQ®) for the..
PR
09/14ABBVIE : and REGENXBIO Announce Eye Care Collaboration
AQ
09/13ABBVIE : Declares Quarterly Dividend
AQ
09/13ABBVIE : to Highlight Its Leadership in Movement Disorders at the International Parkinson ..
AQ
More press releases
Upcoming event on ABBVIE INC.
10/14/21